Federal Courts Weigh Challenges to DEA Cannabis Rescheduling Rule

Multiple Circuit Courts Accept Petitions for Review

At least four federal circuit courts have docketed petitions challenging the DEA's cannabis rescheduling rule, according to court records filed in July 2026. The cases are distributed across the D.C. Circuit, the Fifth Circuit, the Ninth Circuit, and the Tenth Circuit. Petitioners include state attorneys general, industry trade groups, and public-health organizations challenging the rule from opposing directions. Some argue the DEA moved too far. Others say it didn't move far enough.

The DEA finalized the rescheduling rule on April 30, 2026, following a notice-and-comment period that drew more than 43,000 public submissions. The rule became effective May 30, 2026, reclassifying cannabis as a Schedule III controlled substance alongside ketamine and anabolic steroids.

Industry Operators Face Legal Uncertainty on Tax Treatment

Cannabis businesses operating under state licenses have structured their financial and tax planning around Schedule III status, which allows deductions for ordinary business expenses under Section 280E of the Internal Revenue Code. Schedule I classification prohibited those deductions, forcing operators to pay effective federal tax rates exceeding 70 percent in some cases. Schedule III brought that rate closer to standard corporate levels.

If a court vacates the rescheduling rule, operators would revert to Schedule I tax treatment retroactively. The IRS hasn't issued guidance on how it would handle amended returns or refund claims in that scenario. Multi-state operators including Curaleaf, Green Thumb Industries, and Trulieve reported combined tax savings exceeding $800 million in their second-quarter 2026 earnings calls, citing Schedule III reclassification.

Petitioners Challenge Scientific Basis and Procedural Compliance

Several petitions argue the DEA failed to meet the five-factor test required under 21 U.S.C. § 811(c) for scheduling determinations. The statute requires the agency to evaluate a substance's abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, and risk to public health. Petitioners contend the DEA relied on a flawed Health and Human Services recommendation that understated cannabis's abuse liability.

Other petitions challenge the rule on Administrative Procedure Act grounds, alleging the DEA didn't adequately respond to comments raising concerns about pediatric exposure, impaired driving, and workplace safety. The D.C. Circuit petition, filed by a coalition of twelve state attorneys general, argues the agency's cost-benefit analysis ignored state-level enforcement burdens.

Ninth Circuit Petition Seeks Full Descheduling

A separate Ninth Circuit petition filed by advocacy groups including the Last Prisoner Project and NORML argues the DEA should have removed cannabis from the Controlled Substances Act schedules entirely. The petitioners cite the agency's own findings that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances, which they argue supports removal rather than rescheduling.

That petition also challenges the DEA's retention of cannabis flower and extracts under federal cultivation quotas, which remain in place under Schedule III. The agency hasn't expanded the number of federally licensed cultivators beyond the University of Mississippi and a handful of private growers approved in 2023.

Consolidation and Briefing Schedule Expected This Fall

The Judicial Panel on Multidistrict Litigation will likely consolidate the cases into a single circuit court, according to administrative-law attorneys tracking the filings. The D.C. Circuit is the most common destination for challenges to DEA rules, though the Ninth Circuit has also handled cannabis-related petitions in prior years. A consolidation order is expected by September 2026.

Once consolidated, the court will set a briefing schedule. Initial briefs are typically due 60 days after the case is docketed. Oral argument would follow six to nine months later, with a decision likely in mid-2027. The court may issue a stay of the rule during litigation, though such stays are rare in cases where agencies have broad discretion.

What Happens If Courts Vacate the Rule

A court decision vacating the rescheduling rule would immediately return cannabis to Schedule I status, reinstating the 280E tax penalty and triggering compliance questions for state-licensed operators. The DEA would be required to issue a new proposed rule addressing the court's objections, a process that could take 18 to 24 months. State programs would continue operating under their own frameworks in the interim, but federal tax and banking consequences would revert to pre-2026 conditions.

For context on the rescheduling process and its implications, see the CannIntel topic hub on Schedule III rescheduling.

The next procedural milestone is the MDL panel's consolidation decision, expected by early September. Operators and investors will be watching whether any petitioner files a motion for stay pending review, which would signal confidence in the legal challenge and could freeze the rule's effects during litigation.